Evidence for the role of brain norepinephrine and dopamine in "rebound" phenomenon seen during withdrawal after repeated exposure to benzodiazepines.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry; D001960:Bromazepam / Q000008:administration & dosage; D002540:Cerebral Cortex / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D003975:Diazepam / Q000008:administration & dosage; D004298:Dopamine / Q000502:physiology*; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D008526:Medulla Oblongata / Q000378:metabolism; D008636:Mesencephalon / Q000378:metabolism; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000502:physiology*; D011149:Pons / Q000378:metabolism; D051381:Rats; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D014443:Tyrosine / Q000378:metabolism
D014151:Anti-Anxiety Agents; D015102:3,4-Dihydroxyphenylacetic Acid; D014443:Tyrosine; D003975:Diazepam; D004298:Dopamine; D001960:Bromazepam; D009638:Norepinephrine; D006719:Homovanillic Acid